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Abstract
Background: The relationship between non-fasting remnant cholesterol and cardiovascular outcome in the era of
potent statin therapy remained to be elucidated.
Methods: A cohort study of three hundred and twenty eight diabetics diagnosed with new-onset stable coronary
artery disease (CAD) by coronary angiography were enrolled. All cases were followed up for an average duration of
twelve months. The association between baseline remnant cholesterol levels and major cardiovascular outcomes were
evaluated using the receivers operating characteristic (ROC) curves and Cox proportional hazards regression analysis.
Results: During a period of 12-month’s follow-up, 14.3% patients (47/328) underwent pre-specified adverse outcomes.
The remnant cholesterol associated with high sensitivity C-reactive protein, neutrophil count and fibrinogen (R2 = 0.20,
0.12 and 0.14; P = 0.000, 0.036 and 0.010 respectively). Area under the ROC curves (AUC) indicated discriminatory power
of the remnant cholesterol to predict the adverse outcomes for this population (AUC = 0.64, P < 0.005). Kaplan-Meier
curve suggested that the lower levels of remnant cholesterol showed relatively lower cardiac events for diabetic
patients with stable CAD (Log rank X2 = 8.94, P = 0.04). However, according to multivariate Cox proportional
hazards regression, apart from hemoglobin A1C (Hazard ratio [H.R.] =1.38, 95% CI: 1.14–1.66, P = 0.001) and Gensini
scores (H.R. = 1.00, 95% CI: 1.00–1.02; P = 0.035), remnant cholesterol did not qualify as an independent predictor of
adverse prognosis in these settings (H.R. = 1.05, 95% CI: 0.46–2.37, P = 0.909).
Conclusions: Non-fasting remnant cholesterol was associated with inflammatory biomarkers and high incidence of
revascularization, but not qualified as an independent predictor for short-term prognosis of diabetics with new-onset
stable coronary artery disease.
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Background
Remnant cholesterol is the cholesterol content of
triglyceride-rich lipoproteins, composed with very low
density lipoproteins and intermediate density lipoproteins
in the fasting state and of these 2 lipoproteins together
with chylomicron remnants in the non-fasting state [1, 2].
Concerning to our previous investigations, substantial evi-
dence from clinical, general population and genetic studies
have led to a consensus that the cholesterol transported
by remnant lipoproteins or so called remnant cholesterol
is powerful contributor for both coronary artery disease
(CAD) and stroke risk [3–6]. Moreover, it is gradually
clarified that irrespective of the fasting status, defined,
and measured or calculated in different ways, remnant
cholesterol is causally correlated to the risk of CAD
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Mechanistic studies have identified remnant choles-
terol accumulating and infiltrating the endothelial bar-
rier, spuring inflammatory reaction and atherogenic
process in the arterial wall like LDL-C, and observational
studies have also confirmed that elevated remnant choles-
terol was correlated to risk of CAD [8]. By the virture of
their larger size, remnant cholesterol carries 5 to 20 times
as much cholesterol pe particle as LDL-C [9]. Importantly,
unlike native LDL-C, remnant cholesterol can up-regulate
the expression of scavenger receptors and thus promoting
foam cell formation [10]. Thus, genetic studies of variants
associated with elevated remnant cholesterol levels show
that an increment of 1 mmol/L in levels of non-fasting
remnant cholesterol associates with a 2.8-fold increased
risk of CAD [8]. Although triglyceride per se are not quali-
fied as a direct culprits in the atherogenic process, several
prospective studies have suggested the robust predictive
value of triglyceride both for mobility and mortality
[11–16]. It is well-known non-fasting remnant choles-
terol and triglyceride are highly correlated (R2 = 0.96)
[7]. Remnant cholesterol is an important component of
non-HDL-C and non-LDL-C. Prior population studies
have long been suggested that non-HDL-C is a more
robust risk marker for cardiovascular disease than
LDL-C alone [17, 18]. Furthermore, as a result of the
high prevalence of comorbidities and conventional risk
factors among patients with type 2 diabetes, most pa-
tients belong to the highest CAD risk category, and
have substantial residual risk due to remnant choles-
terol even when levels LDL-C persist in recommended
target [19]. Thus, we wonder whether non-fasting
remnant cholesterol is a useful indicator for cardiovas-




From June 2011 through March 2012, a total of 328 type
two diabetic patients with chronic stable angina pectoris
(typical exertional chest pain exhibiting the same pattern
for ≥3 months) were selected from among 1400 con-
secutive patients who underwent diagnostic coronary
angiography (CAG). All enrolled patients were con-
firmed to have stenosis of not less than 50% in at least
one main coronary vessel at our center. Patients with a
history of revascularization or without obstructive coronary
artery lesions and with type 1 diabetes mellitus (DM), acute
coronary syndrome (ACS), significant hematologic disor-
ders (white blood cell count ≤ 3.5*109/L or ≥ 20*109/L), in-
fectious or inflammatory disease, various tumor, severe liver
and/or renal insufficiency were excluded. All subjects en-
rolled were underwent detailed clinical, laboratory, and
angiographic examination for assessment of the cardiac sta-
tus and were asked for their present and past history about
traditional risk factors of CAD such as smoking habits,
hypertension, hyperlipidemia, obesity, diabetes mellitus,
previous stroke, peripheral vascular disease, family history
of CAD and non-cardiovascular diseases.
Hypertension was defined as repeated blood pressure
measurements ≥140/90 mmHg and was assumed to be
present in patients taking anti-hypertensive drugs. Dia-
betes mellitus was diagnosed in patients with fasting
serum glucose level of ≥6.99 mmol/L in multiple deter-
minations or under active treatment with insulin or oral
hypoglycemic agents. The differentia of type 1 and type
2 DM was carried out by multiply elements such as the
age of onset, history of ketosis, concentration of insulin,
curves of insulin release, and clinical manifestation.
Hyperlipidemia was considered to be present in pa-
tients with fasting total cholesterol (TC) ≥ 5.2 mmol/L
or TG ≥ 1.7 mmol/L.
The stable angina pectoris conformed to Canadian
Cardiovascular Society of grade I ~ III and excluded
from ACS. The indications for CAG are in accordance
with the ACC/AHA guidelines for CAG [20]. CAD was
defined as the presence of significant obstructive stenosis,
at least 50% of the vessel lumen diameters, in any of the
main coronary arteries by at least two independent senior
interventional cardiologists based on quantity coronary
angiography (QCA). The severity of CAD was evaluated
with revised Gensini score system [21]. Stent implant-
ation, periprocedural medical treatment and care were
performed according to standard criteria when there were
indicative of revascularization. Post-interventional anti-
platelet therapy consisted of clopidogrel and aspirin with
formal dosage. Drug eluting stents were majorly implant-
ation. The left ventricular ejection fraction was evaluated
by echocardiographer using the area-length methods with
modified Simpson’s rule.
Measurements of biomarkers
Venous blood samples were obtained from each patient
at baseline upon admission. Plasma TC and TG were
measured by enzymatic methods and HDL-C by a direct
method (Roche Diagnostics, Basel, Switzerland). Low-
density lipoprotein cholesterol (LDL-C) was obtained by
Friedewald’s formula (if plasma triglycerides < 4.0 mmol/l),
and otherwise measured directly using ultracentrifugation.
Non-fasting remnant cholesterol was calculated as non-
fasting TC minus HDL-C minus LDL-C. Apoprotein A-1
(ApoA-1) and ApoB were measured by an immunoturbidi-
metric method (Tina-quant, Roche Diagnostics) calibrated
against the World Health Organization/International Fede-
ration of Clinical Chemistry reference standard SP3–07.
The levels of high-sensitivity-CRP were determined using
immunoturbidimetry (Beckmann Assay 360, Bera, Calif.,
USA) according to our previously reported. The levels of
hemoglobin A1C (HbA1C) were measured using the Tosoh
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G7 Automate HPLC Analyzer (TOSOH Bioscience, Japan).
All other included biomarkers were analyzed by standard
biochemical tests, as previously reported [22].
Follow up and study endpoints
The follow-up protocol after discharge of enrolled pa-
tients consisted of a phone or clinic interview. Patients
were followed up for an average duration of 12 months.
During the period, no individual was lost to follow-up.
The pre-specified clinical end points were defined as car-
diac causative death or cardiac death, nonfatal myocardial
infarction (MI), revascularization, and re-hospitalization
due to attack of ACS.
Statistical analysis
All Statistical studies were performed with the SPSS pro-
gram (version 19.0, SPSS, Chicago, Illinois, USA).
The Kolmogorov-Smirnov test was used to test the dis-
tribution pattern. Quantitative variables were expressed as
mean ± standard deviation (SD), and qualitative variables
were expressed as numbers and percentages. According to
the present or absent of pre-specified cardiovascular out-
come, the enrolled population was categorized into two
groups (outcome present group, n = 47; outcome absent
group, n = 281). Continuous variables were analyzed using
either Student’s t-test or the ANOVA methods (normal
distribution) or the Mann-Whiteny U-test or Kruskal-
Wallis test (abnormal distribution). Categorical variables
were compared using chi-squared statistic tests. The rela-
tionship among the remnant cholesterol and other lipid
parameters with inflammatory biomarkers, HbA1C and
Gensini scores were assessed using Spearman’s correlation
analysis. Kaplan-Meier survival curves and receiver operat-
ing characteristic (ROC) curve were all constructed aimed
to demonstrate the discriminatory power of the remnant
cholesterol for pre-specified cardiovascular outcome. In
order to demonstrate whether the remnant cholesterol
could independently provide prognostic information for
diabetic patients with new-onset stable CAD, univariate
and multivariate Cox proportional hazards regression ana-
lysis were performed. A p value of less than 0.05 was con-
sidered as statistically significant.
Results
Baseline characteristics of the study population
The cohort consisted of 240 men (73.3%) and 88 (26.7%)
women aged 34–82 years (mean age 59.4 years). All en-
rolled subjects were diagnosed with type 2 DM and
new-onset stable angina pectoris and referred to CAG.
All patients were received an average of 12-month’s
follow-up (ranged from 20 to 448 days).
The baseline demographic, clinical characteristics and
angiographic findings of the enrolled subjects by the
present or absent of pre-specified cardiovascular outcomes
were summarized in Table 1. Noticeably, compared with
the control, the outcome present group showed increased
levels of HbA1C (7.3 ± 1.5 vs. 6.8 ± 1.4, P = 0.016),
high rank of Gensini scores (45.1 ± 41.8 vs. 32.0 ± 35.2,







Age (years) 59.2 ± 9.4 59.4 ± 9.3 0.891
Male gender 30 (63.8) 210 (74.7) 0.154
BMI (kg/m2) 25.9 ± 3.2 25.4 ± 3.0 0.067
Current smoking 21 (44.7) 160 (56.9) 0.153
Hypertension 36 (76.6) 226 (80.4) 0.557
Hyperlipidemia 95 (80.5) 77 (77.8) 0.557
PVD 0 (0.0) 6 (2.1) 0.599
Prior Stroke 1 (2.1) 12 (4.3) 0.702
Family history of CAD 3 (6.4) 32 (11.4) 0.444
LV-EF (%) 61.7 ± 9.5 62.1 ± 8.1 0.805
Laboratory test
hs-CRP (mg/L) 6.8 ± 1.7 6.0 ± 1.4 0.805
Neutrophil Count (109/L) 3.9 ± 1.0 3.8 ± 1.2 0.797
Fibrinogen (g/L) 138.9 ± 16.6 137.2 ± 14.6 0.095
Hemoglobin A1C (g/L) 7.3 ± 1.5 6.8 ± 1.4 0.016
Creatinine (umol/L) 77.3 ± 15.9 76.2 ± 15.5 0.654
NT-pro-BNP (fmol/mL) 777.9 ± 736.0 731.8 ± 560.1 0.619
Lipid profile
Remnant Cholestero (mmol/L) 0.6 ± 0.6 0.6 ± 0.4 0.390
Triglycerides (mmol/L) 1.9 ± 0.8 1.7 ± 0.9 0.072
Total Cholesterol (mmol/L) 4.2 ± 1.3 3.9 ± 0.9 0.170
LDL-C (mmol/L) 2.5 ± 1.0 2.3 ± 0.8 0.208
HDL-C (mmol/L) 1.1 ± 0.3 1.1 ± 0.3 0.981
Lipoprotein (a) (mg/L) 272.3 ± 286.1 240.1 ± 237.4 0.405
Apoprotein A-1 (g/L) 1.5 ± 0.3 1.4 ± 0.3 0.386
Apoprotein B (g/L) 1.1 ± 0.3 1.0 ± 0.3 0.048
Gensini scores (points) 45.1 ± 41.8 32.0 ± 35.2 0.022
DES Implantation 31 (73.8) 158 (68.7) 0.825
Medicine treatment
Aspirin 46 (97.9) 274 (97.5) 1.000
Clopidogrel 45 (95.7) 269 (95.7) 1.000
Statin 47 (100.0) 272 (96.8) 0.368
Beta-blocker 42 (89.4) 229 (81.5) 0.218
ACE-I/ARB 30 (63.8) 213 (75.8) 0.105
BMI body mass index, PVD peripheral vascular disease, CAD coronary artery
disease, hs-CRP high sensitivity C-reactive protein, NT-pro-BNP N-terminal
pro-Brain natriuretic peptide, LV-FE left ventricular ejection fraction, LDL-C
low density lipoprotein cholesterol, HDL-C high density lipoprotein cholesterol,
DES drug eluting stent, ACE-I angiotensin converting enzyme inhibitors,
ARB angiotensin receptor blocker
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P = 0.022) and mild high concentration of apoB (1.1 ± 0.3
vs. 1.0 ± 0.3, P = 0.048). Except the above three variables,
the remained baseline characteristics between the two
groups were roughly matched (All P > 0.05).
Relation of remnant cholesterol to inflammatory markers
and Gensini scores
According to Spearman’s correlation analysis, the base-
line remnant cholesterol were positively associated with
hs-CRP, neutrophils count, and fibrinogen (correlation
coefficient of R2 = 0.20, 0.12 and 0.14; P = 0.000, 0.036
and 0.010 respectively), but did not correlate with HbA1C
and Gensini scores (All P > 0.05, Table 2). Similarly, the
test for trend by Chi-Squared for levels of HbA1C and
Gensini scores among the tertiles of remnant cholesterol
was not significant (Fig. 1a and b).
Although remnant cholesterol was noticeably corre-
lated to serum triglyceride (R2 = 0.832, P = 0.000),
they did not show same relation to the Gensini
scores (R2 = 0075 vs. 0.115, P = 0.178 and 0.038 res-
pectively). As expected, the levels of LDL-C were as-
sociated with Gensini scores (R2 = 0.125, P = 0.023),
and the lipoprotein (a) correlated to fibrinogen (R2 = 0.208,
P = 0.000).
Utility of remnant cholesterol in predicting short-term
cardiovascular prognosis
During an average period of 12-month follow-up, 47 out
of the 328 patients (14.3%) underwent adverse cardio-
vascular outcome (Fig. 2). The incident of endpoint
events such as revascularization, re-hospitalization due
to attack of angina pectoris and heart failure, none-fatal
myocardial infarction, and cardiac death was 32 (66.7%), 5
(10.4%), 8 (16.7%), and 3 (6.2%) respectively.
As showed in Fig. 3, area under the ROC curves
(AUC) indicated a strong discriminatory power of remnant
cholesterol for the short-term cardiovascular outcomes
(AUC = 0.64, 95% confidential interval [CI] =0.55–0.72;
P = 0.003), with an optimal cutoff value of 0.34 mmo/L.
Moreover, similar to HbA1C and Gensini scores,
Kaplan-Meier curves for cumulative event-free survival
based on the tertiles of admission remnant cholesterol
suggested that the higher levels of remnant cholesterol
showed relatively higher cardiac events for diabetics with
new-onset stable CAD (Log rank Chi-Square = 8.94,
P = 0.011) (Fig. 4a to c).
However, multivariate analysis of Cox proportional
hazards regression (Table 3) indicated that, apart from
HbA1C (Hazard ratio [H.R.] = 1.38, 95% CI: 1.14–1.66,
P = 0.001) and Gensini scores (H.R. = 1.00, 95% CI: 1.00–
1.02; P = 0.035), nonfasting remnant cholesterol did not
qualify as an independent predictor of overall out-
come in these settings (H.R. = 1.05, 95% CI: 0.46–
2.37, P = 0.909).
Discussion
To our knowledge, there have been no previous studies
on determining whether the baseline levels of remnant
cholesterol qualified for a useful predictor independent
of traditional prognostic variables for adverse out-
comes. The main findings of the present study were
summarized as follows. Firstly, according to Speaman’s
Table 2 Spearman’s correlation of remnant cholesterol to inflammatory biomarkers and Gensini scores
Variables Remnant cholesterol Triglyceride LDL-C Lipoprotein (a)
hs-CRP 0.200; <0.000 0.069; <0.211 0.067; <0.224 0.068; <0.221
Neutrophil count 0.116; <0.036 0.105; <0.057 0.017; <0.761 0.093; <0.093
Fibrinogen 0.142; <0.010 0.023; <0.677 −0.022; <0.694 0.208; <0.000
HbA1C 0.081 ;<0.145 0.106; <0.055 0.040; <0.469 −0.033; <0.553
Gensini Scores 0.075; <0.178 0.115; <0.038 0.125; <0.023 0.035; <0.531
hs-CRP high sensitivity C-reactive protein, HbA1c glycosylated hemoglobin A1c, LDL-C low density lipoprotein cholesterol
Fig. 1 Correlation of remnant cholesterol with hemoglobin A1C and Gensini scores (a HbA1C; b Gensini scores)
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correlation, remnant cholesterol was positively associ-
ated with major inflammatory biomarkers such as high
sensitivity C-reactive protein, neutrophil count and fi-
brinogen (R2 = 0.20, 0.12 and 0.14; P = 0.000, 0.036 and
0.010, respectively). Secondly, although remnant choles-
terol was significantly correlated to serum triglyceride
(R2 = 0.832, P = 0.000), they did not show approximate
relation to the Gensini scores (R2 = 0075 vs. 0.115, P =
0.178 and 0.038 respectively). Thirdly, the ROC curve
indicated a matchable discriminatory power of remnant
cholesterol, HbA1C and Gensini scores for the cardio-
vascular outcomes in the study population (AUC for
remnant cholesterol, HbA1C and Gensini scores was
0.64, 0.62 and 0.61; P value was 0.003, 0.007 and 0.002).
Moreover, Kaplan-Meier curves suggested that a higher
concentrations of remnant cholesterol were more fre-
quently accompanied with adverse cardiovascular events
(Log rank Chi-Square = 8.94, P = 0.011). However, multi-
variate analysis in Cox regression model indicated that,
apart from HbA1C and Gensini scores, the baseline
remnant cholesterol did not qualify for an independent
predictor of overall outcome in these settings (H.R. = 1.05,
95% CI: 0.46–2.37, P = 0.909). Obviously, the current
study not only partially confirmed the hypotheses of
previous studies, but also provided novel information
concerning the role of non-fasting remnant cholesterol
in predicting outcomes in diabetic patients with new-
onset stable CAD.
Abundant evidence are indicating that the elevated
levels of remnant cholesterol played an important role in
the development of atherosclerosis, inflammatory and
CAD [1, 5, 7, 23–25]. Patients cohort studies, in-vitro
and animal investigations all support the conception that
elevated levels of remnant cholesterol lead to athero-
sclerosis as the same way as elevated levels of LDL-C
[26]. According to the serial studies from Varbo, et al.,
the hazards ratio for CAD in the highest quintile of
remnant cholesterol (H.R. = 2.3, 95% CI: 1.7–3.1) or
remnant cholesterol/HDL-C (H.R. = 2.6, 95% CI: 2.1–3.2)
were greater than the lowest quintile population [7]. Fur-
thermore, several genetic studies demonstrate evidence of
remnant cholesterol’s being as a causative risk factor for
CAD independent of HDL-C concentration [5, 23, 27–29].
Recent genetic studies with very large samples also indicate
that elevated remnant cholesterol is associated with low-
grade inflammation, whereas elevated LDL-C is not [1].
Coincided with previous studies, the baseline remnant
cholesterol of current study are positively associated
with major inflammatory markers such as hs-CRP,
Fig. 3 Receiver operating characteristic curves showed discriminatory
power of remnant cholesterol, hemoglobin A1C and Gensini scores on
cardiovascular outcomes
Fig. 2 Correlation of remnant cholesterol with cardiovascular outcomes
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Table 3 Cox proportional hazards regression analysis to determine the predictive value of remnant cholesterol for short-term
cardiovascular outcome
Variables Univariate Multivariate
H.R. (95% CI) P-value H.R. (95% CI) P-value
Gender 0.61 (0.33–1.10) 0.099 0.78 (0.36–1.66) 0.512
Age 0.99 (0.97–1.03) 0.941 0.98 (0.94–1.01) 0.195
BMI 1.06 (0.96–1.16) 0.266 1.06 (0.96–1.17) 0.239
Current Somking 1.68 (0.94–2.99) 0.080 1.48 (0.74–2.97) 0.273
Hypertension 0.68 (0.36–1.32) 0.255 0.79 (0.39–1.58) 0.507
Family history of CAD 1.61 (0.49–5.19) 0.427 1.77 (0.53–5.86) 0.352
Gensini Scores 1.01 (1.00–1.02) 0.004 1.00 (1.00–1.02) 0.035
Lipoprotein (a) 1.00 (0.99–1.00) 0.395 1.00 (0.99–1.00) 0.978
LDL-C 1.25 (0.90–1.74) 0.182 1.04 (0.73–1.47) 0.846
Remnant Cholesterol 1.38 (0.67–2.87) 0.378 1.05 (0.46–2.37) 0.909
Hs-CRP 1.02 (0.95–1.09) 0.548 0.98 (0.94–1.01) 0.407
Neutrophil Count 1.09 (0.86–1.40) 0.442 1.01 (0.77–1.32) 0.952
Fibrinogen 1.35 (1.01–1.79) 0.042 1.32 (0.84–2.07) 0.234
Hemoglobin A1C 1.37 (1.16–1.62) 0.000 1.38 (1.14–1.66) 0.001
BMI body mass index, CAD coronary artery disease, LDL-C low density lipoprotein cholesterol, hs-CRP high sensitivity C-reactive protein
Fig. 4 Kaplan-Meier curves for 12-month cumulative survival by the tertiles of remnant cholesterol (a), hemoglobin A1C (b) and Gensini scores (c)
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neutrophil count, and fibrinogen (R2 = 0.20, 0.12 and
0.14; P = 0.000, 0.036 and 0.010 respectively). And as
expected, the elevated of LDL-C is associated with
Gensini scores (R2 = 0.125, P = 0.023) but remnant
cholesterol is not. However, during an average period of
12-month follow-up for the study population, 47 out of
the 328 patients (14.3%) undergo adverse cardiovascu-
lar outcome and the revascularization are highlighted
as the leading cause (66.7%). Therefore, we hypothesize
that the elevated remnant cholesterol at admission may
signify a more serious inflammatory state and athero-
genic course. Besides, all the enrolled patients who have
indication of revascularization received complete revas-
cularization (mainly via percutaneous coronary interven-
tion or implantation of drug eluting stent) during the first
admission.
Furthermore, according to the ROC curve, non-fasting
remnant cholesterol is suggested as a robust discrimin-
ator for the short-term cardiovascular outcomes of dia-
betics with new-onset stable CAD, with an absolute
AUC mildly higher than AUC of HbA1C and Gensini
scores (AUC of remnant cholesterol, HbA1C and Gensini
scores is 0.64, 0.62 and 0.61 respectively; all P < 0.05).
Meanwhile, similar to HbA1C and Gensini scores,
Kaplan-Meier survivor curves suggest that the higher
levels of remnant cholesterol show more incidence of
cardiovascular events in these settings (Log rank Chi-
Square = 8.94, P = 0.011). However, multivariate analysis
in Cox regression model indicates that, apart from
HbA1C and Gensini scores, the independent predictive
value of baseline remnant cholesterol for cardiovascular
events is attenuated after correction for associated vari-
ables and clinical characteristics (H.R. = 1.05, 95% CI:
0.46–2.37, P = 0.909). The underlying cause may consist
at least of three aspects. Utmost, correlation of remnant
cholesterol with low-grade systematic inflammation
and CAD or events are not solely driven by diabetes
mellitus or obesity [24]. Thus, the lack of causal associ-
ation between remnant cholesterol and CAD or Gensini
scores and events in diabetic participants can be ex-
plained by a lack of statistical significance. Moreover,
prior basic study has suggested that genetic variants in
diabetics are not enough to show causality in the presence
of other risk factors [1]. Meanwhile, potent lipid-lowing
therapy will attenuated the causal effect of remnant
cholesterol and thus it may not lead to atherosclerosis in
individuals of diabetics (100% patients of observation
group in study treated with statin). Secondly, irrespective
of fasting states, the circulating levels of remnant choles-
terol have much greater variability than LDL-C [30].
Thirdly, compared with the control group, the observation
group is accompanied with relatively higher HbA1C. Un-
questionable, elevated levels of HbA1C implied not only
severe disorder of glycolipid metabolism, but low-grade of
systematic inflammatory response, vascular dysfunction
and atherosclerotic progress in these settings as well
[12, 31–34]. Nonetheless, although elevated remnant
cholesterol have been increasingly prominent and grad-
ually emerged as a leading impeller for cardiovascular
disease and even LDL-C has been tailored to optimal
levels, the powerful residual risks for diabetic population
is far more than remnant cholesterol alone [5, 35, 36].
The limitations of our study are obvious. First of all,
the sample size of the current study is relatively limited.
Besides, the period of follow-up is comparably in a short
duration and thus unavoidably leads to the bias for to-
tally observing the outcome and/or the severity of CAD.
Utmost, as a post hoc analysis, our investigation fail to
set a strict control and direct compare the predictive
power of remnant cholesterol for patients with and with-
out diabetics. Finally, we do not determine the impact of
genetic variants on remnant cholesterol and other lipids
parameters, and subsequently on the overall outcomes.
Conclusions
Non-fasting remnant cholesterol is associated with inflam-
matory biomarkers and incidents of coronary revasculari-
zation, but not qualified as an independent predictor for
short-term prognosis of diabetics with new-onset stable
CAD in the era of comprehensive revascularization and
potent statin therapeutics. Further studies with larger
sample assessing the predictive usefulness of the remnant
cholesterol for the severity of CAD and its events in varied
background need to be considered.
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